Permeability Enhancers Dramatically Increase Zanamivir Absolute Bioavailability in Rats: Implications for an Orally Bioavailable Influenza Treatment

PLoS ONE

Volumn 8, Issue 4, 2013, Pages

  Holmes, Eric H ^a   Devalapally, Harikrishna ^b   Li, Libin ^b   Perdue, Michael L ^c   Ostrander, Gary K ^a,d  

^a UNIVERSITY OF HAWAII   (United States)

^b Absorption Systems   (United States)

^c FluSolutions Consulting   (United States)

^d FLORIDA STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ZANAMIVIR;

AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DETERMINATION; DRUG FORMULATION; DRUG HALF LIFE; DRUG MARKETING; DRUG PROTEIN BINDING; DRUG RELEASE; DRUG SAFETY; DRUG UPTAKE; ENTERIC COATED TABLET; ENZYME SATURATION; GEL; HUMAN; HUMAN CELL; INFLUENZA; INTESTINE ABSORPTION; INTESTINE MUCOSA PERMEABILITY; LIQUID CHROMATOGRAPHY; LOADING DRUG DOSE; MALE; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PROTEIN TRANSPORT; RAT; TANDEM MASS SPECTROMETRY; TIME TO MAXIMUM PLASMA CONCENTRATION;

ABSORPTION; ADMINISTRATION, ORAL; ANIMALS; BIOLOGICAL AVAILABILITY; BIOLOGICAL TRANSPORT; CACO-2 CELLS; CELL MEMBRANE PERMEABILITY; ENZYME INHIBITORS; HUMANS; INFLUENZA, HUMAN; MALE; NEURAMINIDASE; ORTHOMYXOVIRIDAE INFECTIONS; RATS; RATS, SPRAGUE-DAWLEY; TIME FACTORS; ZANAMIVIR;

RATTUS;

EID: 84876235758     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0061853     Document Type: Article

References (21)

1. World Health Organization (2009) World Health Organization Fact Sheet 211. April 2009.
2. Nicholls H, (2006) Pandemic Influenza: The Inside Story. PLoS Biology 4: e50.
3. Moscona A, (2005) Neuraminidase inhibitors for influenza. N Engl J Med 353: 1363-1373.
4. Garman E, Laver WG (2005) The structure, function, and inhibition of influenza virus neuraminidase. In: Viral Membrane Proteins: Structure, Function, and Drug Design, Wolfgang Fischer (ed). Kluwer Academic/Plenum Publishers, New York.
5. Coleman PM, (1994) Influenza viral neuraminidase: structure, antibodies, and inhibitors. Protein Science 3: 1687-1696.
6. Vagrhese JN, Smith PW, Sollis SL, Blick TJ, Sahasrabudhe A, et al. (1998) Drug design against a shifting target: a structural basis for resistance to inhibitors in a variant of influenza virus neuraminidase. Structure 6: 735-746.
7. Kim CU, Lew W, Williams MA, Liu H, Zhang L, et al. (1997) Influenza neuraminidase inhibitors possessing a novel hydrophobic interaction in the enzyme active site: design, synthesis, and structural analysis of carbocyclic sialic acid analogues with potent anti-influenza activity. J Am Chem Soc 119: 681-690.
8. Russell RJ, Haire LF, Stevens DJ, Collins PJ, Pin YP, et al. (2006) The structure of H5N1 avian influenza neuraminidase suggests new opportunities for drug design. Nature 443: 445-49.
9. Babu YS, Chand P, Bantia S, Kotian P, Dehghani A, et al. (2000) BCX-1812 (RWJ-270201): discovery of a novel, highly potent, orally active, and selective influenza neuraminidase inhibitor through structure-based drug design. J Med Chem 43: 3482-6.
10. Sudbeck EA, Jedrzejas MJ, Singh S, Brouillette WJ, Air GM, et al. (1997) Guanidinobenzoic acid inhibitors of influenza virus neuraminidase. J Mol Biol 267: 584-94.
11. Chand P, Babu YS, Bantia S, Chu N, Cole LB, et al. (1997) Design and synthesis of benzoic acid derivatives as influenza neuraminidase inhibitors using structure-based drug design. J Med Chem 40: 4030-52.
12. von Itzstein M, Wu WY, Kok GB, Pegg MS, Dyason JC, et al. (1993) Rational design of potent sialidase-based inhibitors of influenza virus replication. Nature 363: 418-23.
13. Aoki FY, Hayden FG, (1999) Zanamivir. A potent and selective inhibitor of influenza A and B viruses. Clin Pharmacokinet 36 Suppl 1: v-ix.
14. Cass LM, Efthymiopoulos C, Bye A, (1999) Pharmacokinetics of zanamivir after intravenous, oral, inhaled or intranasal administration to healthy volunteers. Clin Pharmacokinet 36 Suppl 1: 1-11.
15. García-Sosa AT, Sild S, Maran U, (2008) Design of multi-binding-site inhibitors, ligand efficiency, and consensus screening of avian influenza H5N1 wild-type neuraminidase and of the oseltamivir-resistant H274Y variant. J Chem Inf Model 48: 2074-2080.
16. Li W, Escarpe PA, Eisenberg EJ, Cundy KC, Sweet C, et al. (1998) Identification of GS 4104 as an orally bioavailable prodrug of the influenza virus neuraminidase inhibitor GS 4071. Antimicrob Agents Chemother 42: 647-53.
17. Mendel DB, Tai CY, Escarpe PA, Li W, Sidwell RW, et al. (1998) Oral administration of a prodrug of the influenza virus neuraminidase inhibitor GS 4071 protects mice and ferrets against influenza infection. Antimicrob Agents Chemother 42: 640-6.
18. Miller JM, Dahan A, Gupta D, Varghese S, Amidon GL, (2010) Enabling the intestinal absorption of highly polar antiviral agents: ion-pair facilitated membrane permeation of zanamivir heptyl ester and guanidino oseltamivir. Mol Pharm 7: 1223-34.
19. Gupta SV, Gupta D, Sun J, Dahan A, Tsume Y, et al. (2011) Enhancing the intestinal membrane permeability of zanamivir: a carrier mediated prodrug approach. Mol Pharm. 8: 2358-67.
20. Liu KC, Lee PS, Wang SY, Cheng YS, Fang JM, et al. (2011) Intramolecular ion-pair prodrugs of zanamivir and guanidine-oseltamivir. Bioorg Med Chem 19: 4796-802.
21. -2009 Influenza Season Week 32 ending August 15, 2009. Flu Activity & Surveillance. Centers for Disease Control and Prevention (CDC). August 21, 2009. Available: http://www.cdc.gov/flu/weekly/weeklyarchives2008-2009/weekly32.htm.